Literature DB >> 35777394

Adaptive Phase 1 Design in Radiation Therapy Trials.

Nolan A Wages1, Thomas M Braun2, Daniel P Normolle3, Matthew J Schipper4.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35777394      PMCID： PMC9260906          DOI： 10.1016/j.ijrobp.2022.02.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   8.013


× No keyword cloud information.
  39 in total

1.  A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Authors:  Thomas M Braun; Shufang Wang
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

2.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

3.  Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.

Authors:  Nolan A Wages; Christopher Tait
Journal:  J Biopharm Stat       Date:  2014-06-06       Impact factor: 1.051

4.  Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.

Authors:  Amye Tevaarwerk; George Wilding; Jens Eickhoff; Rick Chappell; Carolyn Sidor; Jamie Arnott; Howard Bailey; William Schelman; Glenn Liu
Journal:  Invest New Drugs       Date:  2011-01-12       Impact factor: 3.850

5.  Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.

Authors:  Ying Yuan; Ruitao Lin; Daniel Li; Lei Nie; Katherine E Warren
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 12.531

6.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.

Authors:  Thomas M Braun
Journal:  Control Clin Trials       Date:  2002-06

Review 7.  Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development.

Authors:  Elad Sharon; Mei-Yin Polley; Michael B Bernstein; Mansoor Ahmed
Journal:  Radiat Res       Date:  2014-07-08       Impact factor: 2.841

8.  First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.

Authors:  Ajay K Gopal; Ronald Levy; Roch Houot; Sandip P Patel; Leslie Popplewell; Caron Jacobson; Xinmeng J Mu; Shibing Deng; Keith A Ching; Ying Chen; Craig B Davis; Bo Huang; Kolette D Fly; Aron Thall; Adrian Woolfson; Nancy L Bartlett
Journal:  Clin Cancer Res       Date:  2020-03-06       Impact factor: 12.531

9.  Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.

Authors:  Ruitao Lin; Ying Yuan
Journal:  Biostatistics       Date:  2020-10-01       Impact factor: 5.899

10.  Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.

Authors:  R de Haan; E van Werkhoven; M M van den Heuvel; H M U Peulen; G S Sonke; P Elkhuizen; M W M van den Brekel; M E T Tesselaar; C Vens; J H M Schellens; B van Triest; M Verheij
Journal:  BMC Cancer       Date:  2019-09-10       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.